<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35598239</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1875-6697</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Current computer-aided drug design</Title>
          <ISOAbbreviation>Curr Comput Aided Drug Des</ISOAbbreviation>
        </Journal>
        <ArticleTitle>In silico approach and molecular docking studies of potent bioactive compounds of Carica papaya as anti-breast cancer agents.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/1573409918666220519112027</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Breast cancer is one of the greatest global dilemmas and the current treatment option is using partial agonists/antagonists to target hormone receptors. Estrogen and aromatase enzymes play important roles in breast cancer. The excessive activity or low-level production of estrogen causes various hormonal problems, particularly breast cancer. Potent breast cancer drugs are Tamoxifen, Paclitaxel, Cyclophosphamide, Trastuzumab, etc., and aromatase inhibitors such as Anastrozole, Letrozole and Exemestane, etc. Generally, Breast cancer drugs initiate a few serious side effects in humans.</AbstractText>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study has attempted to identify alternative drug candidates from Carica papaya with fewer side effects for the treatment of breast cancer.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">To achieve this, we have utilized the computational methods for predicting the properties of bioactive compounds from Carica papaya and determining the target binding affinities using the Schrödinger suite (Maestro 9.5). The ligands and target protein were obtained from the well-known database. There are 35 bioactive compounds identified from Carica papaya, were drawn using ChemDraw software and performed Ligand preparation wizard. QikProp is used for Absorption, Distribution, Metabolism, and Excretion (ADME) analysis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">From the docking studies, the phytocompounds such as Chlorogenic acid, Myricetin, Quercetin, Isorhamnetin, Catechin showed the highest Glide scores. Among the five bioactive phytocompounds, Chlorogenic acid shows a more interesting Gscore with good binding energy compared with the standards Tamoxifen, Anastrozole, and Letrozole. ADME profiling of the phytocompounds was investigated to find the pharmacokinetic characteristics and drug-likeness Conclusion: Carica papaya derived phytocompounds act as an antiestrogen or aromatase inhibitor to regulate the levels of estrogen and the implications for postmenopausal women and reduce the risk of breast cancer. Therefore, we propose these top five bioactive phytocompound for further investigation through in vitro and in vivo studies.</AbstractText>
          <CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Maruthanila</LastName>
            <ForeName>V L</ForeName>
            <Initials>VL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar, Chidambaram-608 002, Tamil Nadu, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elancheran</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Annamalai University, Annamalainagar, Chidambaram-608 002, Tamil Nadu, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mirunalini</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar, Chidambaram-608 002, Tamil Nadu, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Comput Aided Drug Des</MedlineTA>
        <NlmUniqueID>101265750</NlmUniqueID>
        <ISSNLinking>1573-4099</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Aromatase enzyme</Keyword>
        <Keyword MajorTopicYN="N">Carica papaya</Keyword>
        <Keyword MajorTopicYN="N">Estrogen receptor</Keyword>
        <Keyword MajorTopicYN="N">Maestro 9.5.</Keyword>
        <Keyword MajorTopicYN="N">Phenolic acids</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>14</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35598239</ArticleId>
        <ArticleId IdType="doi">10.2174/1573409918666220519112027</ArticleId>
        <ArticleId IdType="pii">CAD-EPUB-123763</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
